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Abstract
Background: The purpose of this study was to estimate precise age-specific tubo-ovarian carcinoma (TOC) and breast cancer
(BC) risks for carriers of pathogenic variants in RAD51C and RAD51D. Methods: We analyzed data from 6178 families, 125 with
pathogenic variants in RAD51C, and 6690 families, 60 with pathogenic variants in RAD51D. TOC and BC relative and
cumulative risks were estimated using complex segregation analysis to model the cancer inheritance patterns in families
while adjusting for the mode of ascertainment of each family. All statistical tests were two-sided. Results: Pathogenic
variants in both RAD51C and RAD51D were associated with TOC (RAD51C: relative risk [RR]¼7.55, 95% confidence interval [CI]
¼ 5.60 to 10.19; P¼510-40; RAD51D: RR¼7.60, 95% CI ¼ 5.61 to 10.30; P¼510-39) and BC (RAD51C: RR¼1.99, 95% CI ¼ 1.39 to
2.85; P¼1.5510-4; RAD51D: RR¼1.83, 95% CI ¼ 1.24 to 2.72; P¼ .002). For both RAD51C and RAD51D, there was a suggestion
that the TOC relative risks increased with age until around age 60 years and decreased thereafter. The estimated cumulative
risks of developing TOC to age 80 years were 11% (95% CI ¼ 6% to 21%) for RAD51C and 13% (95% CI ¼ 7% to 23%) for RAD51D
pathogenic variant carriers. The estimated cumulative risks of developing BC to 80 years were 21% (95% CI ¼ 15% to 29%) for
RAD51C and 20% (95% CI ¼ 14% to 28%) for RAD51D pathogenic variant carriers. Both TOC and BC risks for RAD51C and
RAD51D pathogenic variant carriers varied by cancer family history and could be as high as 32–36% for TOC, for carriers with
two first-degree relatives diagnosed with TOC, or 44–46% for BC, for carriers with two first-degree relatives diagnosed with BC.
Conclusions: These estimates will facilitate the genetic counseling of RAD51C and RAD51D pathogenic variant carriers and
justify the incorporation of RAD51C and RAD51D into cancer risk prediction models.
Genetic testing through multigene cancer panels is widely avail-
able and has become an integral part of the genetic counseling and
oncologic practice used to inform clinical management options.
RAD51C and RAD51D are included on widely available cancer pan-
els because of the reported associations of pathogenic variants in
these genes with tubo-ovarian carcinoma (TOC) (1–3). However,
the optimal interpretation of gene-panel testing results requires
precise cancer risk estimates for pathogenic variants in RAD51C.
The reported TOC risks for RAD51C pathogenic variant car-
riers vary widely with odds ratio (OR) estimates ranging from
3.4 to 15.8 based on case-control studies and a relative risk (RR)
of 5.9 using family-based segregation analysis (Supplementary
Table 1, available online). Similarly, the reported TOC odds ra-
tios and relative risks for RAD51D pathogenic variant carriers
ranged from 6.3 to 12.0 (Supplementary Table 1, available on-
line). There has been conflicting evidence for the association of
both RAD51C and RAD51D pathogenic variants with breast can-
cer (BC) risk. Some studies reported an increased BC risk (OR
estimates for RAD51C ¼ 5.9–8.7; RAD51D ¼ 3.1–8.3), but others
reported no statistically significant associations (Supplementary
Table 2, available online) (4–6).
A concern with published risk estimates based on case-
control studies has been that cases may have been selected on
the basis of cancer family history, which may confound the
associations and/or lead to an overestimation of cancer risks be-
cause of the enrichment of cases for pathogenic variants.
Furthermore, the pathogenic variant frequencies in controls
come predominantly from publicly available resources and may
come from populations that do not closely match the case pop-
ulation. Therefore, some of the published risk estimates may be
susceptible to selection biases or biases because of population
stratification and cannot be readily applied in the counseling
process. Family- or pedigree-based approaches, with appropri-
ate ascertainment corrections in the analysis, which adjust for
the ascertainment process of each family, address directly such
potential biases and can result in more precise risk estimates
because of the use of information on both genotyped and non-
genotyped family members. Here, we use a large collection of
families with RAD51C and/or RAD51D pathogenic variants to es-
timate age-specific TOC and BC risks and assess how these vary
by family history of cancer.
Methods
Families
Families were enrolled between 1996 and 2017 through 28 study
centers from 12 countries from Europe and North America and
were ascertained through RAD51C or RAD51D variant screening
of families with multiple TOC- or BC-affected members (24 stud-
ies) and RAD51C or RAD51D variant screening of TOC or BC
patients unselected for cancer family history (three studies).
One study included families ascertained through both schemes.
Four studies provided data on all families screened for RAD51C
or RAD51D variants, irrespective of the result (Supplementary
Table 3, available online). Participants provided informed con-
sent in accordance with institutional review board policies and
local practices. The list of study centers and ascertainment cri-
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Variants
Pathogenic variants including frameshift, nonsense, canonical
splice sites, and large genomic deletions were considered in the
analyses. Variants in the last exon were excluded. We estimated
the population RAD51C and RAD51D variant using the UK Biobank
exome sequencing dataset (http://www.ukbiobank.ac.uk).
Statistical Analysis
Cancer inheritance patterns and observed genotypes in families
were modeled using complex segregation analysis to estimate
TOC and BC relative risks simultaneously (7, 8) in the pedigree
analysis software Mendel, version 3.3 (9).
Family members were followed from birth until the age at
first cancer diagnosis (excluding nonmelanoma skin cancer),
age at death, age at last follow-up, age at risk-reducing surgery
(bilateral mastectomy in the BC analyses or bilateral salpingo-
oophorectomy in the TOC analyses if they occurred at least 1
year prior to cancer diagnosis), or age 80 years, whichever oc-
curred first. Women diagnosed with a first TOC or BC were as-
sumed to be affected at the age of diagnosis, whereas women
with any other type of first cancer diagnosis were censored at
the age of diagnosis and were assumed as unaffected. Missing
ages were inferred from other information (Supplementary
Methods, available online). Individuals with unknown disease
status and no age information were censored at age 0 years.
Each female was assumed to be at risk of developing TOC
and BC assuming that the probability of developing TOC was in-
dependent of the probability of developing BC conditional on
genotype. We modeled the TOC and BC incidences so that they
depend on the underlying assumed genetic effects
(Supplementary Methods, available online). Two main genetic
models were fitted: a major-gene model that assumed all famil-
ial aggregation of TOC and BC was explained by RAD51C or
RAD51D and a major-gene plus polygenic component model
that considered an additional residual familial component rep-
resenting other unobserved genetic effects not due to RAD51C
or RAD51D (10,11) (Supplementary Methods, available online).
Models were fitted in which the log-relative risk for RAD51C or
RAD51D pathogenic variant carriers relative to population inci-
dences were assumed to be either constant across the whole
age range, constant for specific age groups, or a piecewise linear
function of age (Supplementary Methods, available online). We
used country, cohort, and population age-specific incidences
and constrained the overall cancer age-specific incidences over
all assumed genetic effects to agree with the population age-
specific incidences (11,12) (Supplementary Methods, available
online).
Because families were ascertained through different criteria
across studies, we employed the ascertainment assumption-
free approach to adjust for ascertainment by computing the
pedigree likelihood conditional on all data relevant to the ascer-
tainment (13–15) (Supplementary Methods, available online).
Noninformative families, for which no additional information
was available beyond the data relevant to the ascertainment,
were excluded from the analysis.
The most parsimonious models were selected by either com-
paring the Akaike information criterion (AIC) for nonnested
models, by selecting the model with the smaller AIC, or using
the likelihood ratio test (LRT) for nested models. The hypothesis
that the relative risk is 1.00 was assessed using a Wald test
statistic. All statistical tests were two-sided. Statistical signifi-
cance was considered as a P value less than 0.05.
Results
Variants and Families
A total of 7216 families eligible for pathogenic variant analysis
were submitted to the coordinating center, where 6049 were
identified through individuals with multiple relatives diagnosed
with TOC or BC, and 1167 were identified through women diag-
nosed with TOC or BC unselected for cancer family history.
After adjustment for ascertainment, 6178 and 6690 families
were eligible for the RAD51C and RAD51D penetrance analysis,
respectively (Supplementary Tables 3 and 4, available online).
These included 215 women with RAD51C pathogenic variants
(137 were TOC or BC cases) from 125 families and 92 women
with RAD51D pathogenic variants (66 were TOC or BC cases)
from 60 families (Table 1). Full lists of the RAD51C and RAD51D
pathogenic variants in this dataset are summarized in
Supplementary Tables 5 and 6 (available online). The patho-
genic variant population frequencies used in the segregation
analysis model were estimated to be 0.00022 for RAD51C and
0.00026 for RAD51D based on 42 325 cancer-free individuals
from the UK Biobank exome sequencing data.
Risk Models
The genetic models that included a residual polygenic compo-
nent for TOC and BC provided better fits to the data than the
major-gene models for both RAD51C and RAD51D (results for
major gene models not shown). For RAD51C, using a constant
relative risk with age, the AIC for the major gene model was
4363 compared with 4346 for the BC polygenic model and with
4336 for the TOC polygenic model (Table 2). For RAD51D, the AIC
for the major-gene model was 4187 compared with 4178 for the
BC polygenic model and with 4160 for the TOC polygenic model
(Table 2). Therefore, we based all subsequent analyses on the
major-gene plus polygenic component models.
TOC Risk
The estimated TOC relative risks were 7.55 (95% CI ¼ 5.60 to
10.19; P¼ 5 10-40) for RAD51C and 7.60 (95% CI ¼ 5.61 to 10.30;
P¼ 5 10-39) for RAD51D pathogenic variant carriers when rela-
tive risks were assumed to be constant with age (Table 2). When
separate relative risks were estimated for each age-decade,
there was a suggestion that relative risks increased with age un-
til 60–69 years and then decreased for RAD51C pathogenic vari-
ant carriers. A similar pattern was seen for RAD51D pathogenic
variant carriers but the relative risk peaked in the 50–59 years
age group (Table 2). These models provided a better fit to the
data than the models with a constant RR for both RAD51C (LRT,
degrees of freedom [df] ¼ 4; P¼ .04) and RAD51D (LRT, df ¼ 4;
P¼ .02). When we partitioned age into younger than 50 years
and 50 years and older, the estimated TOC relative risks were
higher for ages 50 years and older for both RAD51C (RR¼ 9.44,
95% CI ¼ 6.63 to 13.45 for ages 50 years and older; RR¼ 4.97, 95%
CI ¼ 2.75 to 8.97 for ages younger than 50 years) and RAD51D
pathogenic variant carriers (RR¼ 10.56, 95% CI ¼ 7.48 to 14.91 for
ages 50 years and older; RR¼ 3.23, 95% CI ¼ 1.36 to 7.71 for
ages younger than 50 years). The model with separate relative
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this two age-group model in either RAD51C (LRT, df¼ 3; P¼ .12)
or RAD51D (LRT, df¼ 3; P¼ .51). To smooth the relative risk
changes over age, we fitted models in which the log-relative
risk was assumed to be a piecewise linear function of age. For
RAD51C, there was statistically significant evidence that the rel-
ative risk increases with age (P¼ .004) from age 30 to 60 years
and then decreases. Similarly for RAD51D, there was statisti-
cally significant evidence that the relative risk increases with
age (P¼ .002) from age 30 to 58 years and then decreases. The
piecewise linear models were the most parsimonious with the
lowest AIC (Table 2). Under these models, the estimated cumu-
lative risks of developing TOC for a woman with a RAD51C path-
ogenic variant to age 50 years was 1% (95% CI ¼ 0.6% to 2%) and
11% (95% CI ¼ 6% to 21%) to age 80 years; the corresponding cu-
mulative TOC risks were 0.8% (95% CI ¼ 0.5% to 2%) to age 50
years and 13% (95% CI ¼ 7% to 23%) to age 80 years for a woman
with a RAD51D pathogenic variant, assuming the UK incidences
(Figure 1 and Table 3). The corresponding risks using US popula-
tion incidences are shown in Supplementary Table 7 (available
online).
Breast Cancer Risk
The estimated BC relative risk was 1.99 (95% CI ¼ 1.39 to 2.85;
P¼ 1.55 10-4) for RAD51C and 1.83 (95% CI ¼ 1.24 to 2.72;
P¼ .002) for RAD51D pathogenic variant carriers when relative
risk was constant with age (Table 2). When relative risks varied
by age-decade, for RAD51C, the statistically significant associa-
tion was restricted to ages 30–49 years, but this model did not fit
better than the model with a constant relative risk (LRT, df¼ 5;
P¼ .37). When only two age groups were assumed, there was
further evidence of higher BC relative risk in younger ages (20–
49 years: RR¼ 2.42, 95% CI ¼ 1.61 to 3.63) compared with ages 50
years and older (RR¼ 1.36, 95% CI ¼ 0.70 to 2.63), but the model
with a constant relative risk remained the most parsimonious.
For RAD51D, a U-shape pattern was observed with higher rela-
tive risk estimates in ages 20–39 and 70–79 years (Table 2), but
the model with constant relative risk was the most parsimoni-
ous (LRT, df¼ 4; P¼ .59, comparing against the age-specific RR
model; Table 2). The estimated cumulative risks of developing
BC to age 50 years were 4% (95% CI ¼ 3% to 6%) for RAD51C and
4% (95% CI ¼ 2% to 5%) for RAD51D pathogenic variant carriers
and to age 80 years were 21% (95% CI ¼ 15% to 29%) for RAD51C
and 20% (95 CI ¼ 14% to 28%) for RAD51D pathogenic variant car-
riers assuming UK incidences (Figure 1 and Table 3;
Supplementary Table 7, available online, assuming US incidences).
Birth Cohort and Variant Screening Sensitivity
We assessed whether the estimated risks vary by birth cohort
by estimating separate relative risks for different birth cohort
groupings (Supplementary Table 8, available online). There was
a suggestion of increasing BC risks with more recent birth co-
hort, but the differences were not statistically significant.
Similarly, there were no statistically significant differences in
the TOC relative risk estimates between cohort groupings for ei-
ther RAD51C or RAD51D relative risks. We also assessed the im-
pact on the results of assuming a reduced mutation screening
sensitivity when including RAD51C/D test-negative families
(Supplementary Methods, available online). As the mutation
screening sensitivity parameter decreased, the estimated TOC
and BC relative risks increased (Supplementary Table 9, avail-
able online).
Predicted Risks by Family History
The most parsimonious models included a residual familial
polygenic component. Under this model, the risk of developing
Table 1. Summary of women by mutation, disease status, and age among the families with RAD51C and RAD51D pathogenic variants
Age, y
Pathogenic variant carriers Tested noncarriers Untested
Unaffected BC TOC Unaffected BC TOC Unaffected BC TOC
RAD51C (n ¼ 1794 from 125 families)
<20 1 0 0 1 0 0 88 0 1
20–29 6 1 0 2 0 0 73 4 1
30–39 18 21 2 12 1 0 128 15 6
40–49 26 25 10 24 4 0 156 35 12
50–59 14 16 27 11 3 0 143 30 21
60–69 9 6 20 9 5 2 161 35 24
70–80 4 4 6 3 1 0 368 15 15
Missing* 0 0 0 0 0 0 172 0 0
Total† 78 73 65 62 14 2 1289 134 80
RAD51D (n ¼ 935 from 60 families)
<20 1 0 0 2 0 0 26 0 0
20–29 2 1 0 2 0 0 40 0 0
30–39 7 7 2 6 0 0 54 7 4
40–49 7 11 4 8 2 1 80 19 7
50–59 7 8 17 8 0 0 85 28 19
60–69 1 3 10 5 2 0 87 13 14
70–80 1 0 3 0 0 0 192 7 5
Missing* 0 0 0 0 0 0 120 0 0
Total 26 30 36 31 4 1 684 74 49
*Individuals with missing phenotype information were censored at age 0 years. BC ¼ breast cancer; TOC ¼ tubo-ovarian carcinoma.
†There are three individuals with two cancers diagnosed at the same age and counted in both BC and TOC: one is RAD51C pathogenic variant carrier, and the other two
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TOC or BC for RAD51C/D pathogenic variant differs by cancer
family history. The predicted risk of developing TOC to age
80 years varies from 11% (95% CI ¼ 6% to 21%) for RAD51C and
13% (95% CI ¼ 7% to 23%) for RAD51D pathogenic variant carriers
with no family history of TOC in first- and second-degree rela-
tives to 32% (95% CI ¼ 20% to 50%) for RAD51C and 36% (95% CI ¼
23% to 53%) for RAD51D pathogenic variant carriers whose
mother and sister developed TOC at age 50 years (Figure 2;
Supplementary Tables 10 and 11, available online). Similarly,
the predicted cumulative risk of developing BC to age 80 years
varies from 20% (95% CI ¼ 15% to 28%) for RAD51C and 19% (95%
CI ¼ 13% to 27%) for RAD51D pathogenic variant carriers with an
Table 2. Estimated tubo-ovarian carcinoma and breast cancer relative risk for RAD51C and RAD51D pathogenic variant carriers
Cancer and models considered Age, y RR (95% CI) P* LRT P† AIC Best fitting models
RAD51C
Tubo-ovarian carcinoma
Age-constant model 30–79 7.55 (5.60 to 10.19) 5  10-40 4335.8
Age-specific model for each decade of age 30–39 2.85 (0.46 to 17.70) 0.04 4334.0
40–49 5.94 (3.09 to 11.43)
50–59 8.55 (5.10 to 14.33)
60–69 13.90 (8.45 to 22.88)
70–79 2.54 (0.53 to 12.27)
Age-specific model, separate parameters
for two age groups: 30–50 and 50–80 y
30–49 4.97 (2.75 to 8.97) 0.048 4333.8
50–79 9.44 (6.63 to 13.45)






Age-constant model 20–79 1.99 (1.39 to 2.85) 1.55  10-4 4346.4 Yes
Age-specific model, separate parameters
for each decade of age
20–29 1.19 (0.09 to 16.12) 0.37 4351.0
30–39 3.25 (1.60 to 6.62)
40–49 2.50 (1.41 to 4.45)
50–59 0.96 (0.34 to 2.71)
60–69 1.54 (0.45 to 5.36)
70–79 2.57 (0.61 to 10.81)
Age-specific model, separate parameters
for two age groups: 20–50 and 50–80 y
20–49 2.42 (1.61 to 3.63) 0.12 4346.0
50–79 1.36 (0.70 to 2.63)
RAD51D
Tubo-ovarian carcinoma
Age-constant model 30–79 7.60 (5.61 to 10.30) 5  10-39 4160.0
Age-specific model for each decade of age 30–39 3.60 (0.78 to 16.75) 0.02 4155.8
40–49 3.19 (1.04 to 9.72)
50–59 12.54 (7.62 to 20.63) —
60–69 10.60 (6.10 to 18.41) —
70–79 4.94 (1.34 to 18.26) —
Age-specific model, separate parameters
for two age groups: 30–50 and 50–80 y
30–49 3.23 (1.36 to 7.71) — 0.002 4152.1
50–79 10.56 (7.48 to 14.91) —






Age-constant model 20–79 1.83 (1.24 to 2.72) 0.0002 4177.9 Yes
Age-specific model, separate parameters
for each decade of age except for 20–39
y age group
20–39 2.25 (1.25 to 4.04) — 0.59 4183.1
40–49 1.46 (0.69 to 3.09) —
50–59 1.56 (0.69 to 3.51) —
60–69 1.63 (0.54 to 4.98) —
70–79 4.19 (1.51 to 11.62) —
Age-specific model, separate parameters
for two age groups: 20–50 and 50–80 y
20–49 1.84 (1.12 to 3.02) — 1.00 4179.9
50–79 1.83 (1.02 to 3.26) —
*The P values assessing the null hypothesis of RR¼1.00. AIC ¼ Akaike information criterion; CI ¼ confidence interval; RR ¼ relative risk.
†Likelihood ratio tests (LRT) comparing each model against the model with a constant RR.
‡logRR(t) ¼ a þ b1(t  30) if t 2 [30,60); logRR(t) ¼ a þ b1  30 þ b2(t  60) if t 2 [60,80), where a¼0.49 (95% CI ¼ 0.80 to 1.78), b1 ¼ 0.076 (95% CI ¼ 0.023 to 0.13), b2 ¼ 0.12
(95% CI ¼ 0.23 to 0.0036).
§logRR(t) ¼ a þ b1(t  30) if t 2 [30,58); logRR(t) ¼ a þ b1  28 þ b2(t  58) if t 2 [58,80), where a¼0.010 (95% CI ¼ 1.49 to 1.51), b1 ¼ 0.097 (95% CI ¼ 0.034 to 0.16), b2 ¼
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unaffected mother at age 50 years and unaffected maternal
grandmother at age 70 years to 46% (95% CI ¼ 6% to 56%) for
RAD51C and 44% (95% CI ¼ 33% to 55%) for RAD51D pathogenic
variant carriers with two first-degree relatives diagnosed with
BC (Figure 2; Supplementary Tables 10 and 11, available online).
Discussion
This is the largest family-based study to date to estimate age-
specific relative and absolute TOC and BC risks for RAD51C and
RAD51D pathogenic variant carriers, confirming that RAD51C
and RAD51D pathogenic variants are associated with TOC and
BC risks, which vary by cancer-family history.
Several case-control studies have estimated the association
between RAD51C and RAD51D pathogenic variants and TOC
(Supplementary Table 1, available online). However, these stud-
ies had limited statistical power and the odds ratio estimates,
ranging from 3.4 to 15.8, were imprecise with broad confidence
intervals (Supplementary Table 1, available online). The
reported associations with BC risk have been unclear with con-
flicting evidence (Supplementary Table 2, available online). A
complicating factor in interpreting the results from some BC
case-control studies includes the fact that BC cases may have
been selected on the basis of family history of both BC and TOC,
which may confound the BC associations given the known TOC
association, and publicly available controls were often not
closely matched to the case populations. In contrast, the pre-
sent analysis considered the ascertainment process for each
family separately and modeled the simultaneous associations
with TOC and BC. In addition, family-based analyses closely
Figure 1. Estimated age-specific tubo-ovarian carcinoma and breast cancer cumulative risks in RAD51C and RAD51D pathogenic variant carriers. The shaded areas cor-
respond to the 95% confidence intervals.
Table 3. Estimated age-specific cancer incidences and cumulative cancer risks for RAD51C and RAD51D pathogenic variant carriers
Age, y
RAD51C pathogenic variant carriers RAD51D pathogenic variant carriers
BC TOC BC TOC
Estimated incidences per 1000 person-years (95% CI)*
30 0.4 (0.2 to 0.5) 0.05 (0.01 to 0.2) 0.3 (0.2 to 0.5) 0.03 (0.007 to 0.1)
40 2 (1 to 3) 0.3 (0.2 to 0.8) 2 (1 to 2) 0.3 (0.1 to 0.7)
50 5 (3 to 6) 2 (1 to 3) 4 (3 to 6) 2 (1 to 3)
60 6 (4 to 9) 7 (4 to 11) 6 (4 to 9) 6 (4 to 8)
70 7 (5 to 10) 3 (1 to 8) 7 (4 to 10) 5 (2 to 9)
79 8 (5 to 11) 1 (0.2 to 8) 7 (5 to 11) 3 (0.9 to 12)
Estimated cumulative risks, % (95% CI)*
30 0.1 (0.08 to 0.2) 0.02 (0.02 to 0.02) 0.1 (0.07 to 0.2) 0.02 (0.02 to 0.02)
40 1 (0.7 to 1) 0.2 (0.08 to 0.4) 0.9 (0.6 to 1) 0.1 (0.06 to 0.3)
50 4 (3 to 6) 1 (0.6 to 2) 4 (2 to 5) 0.8 (0.5 to 2)
60 9 (6 to 12) 4 (3 to 7) 8 (6 to 12) 4 (3 to 7)
70 15 (11 to 21) 9 (6 to 14) 14 (10 to 20) 9 (6 to 14)
80 21 (15 to 29) 11 (6 to 21) 20 (14 to 28) 13 (7 to 23)
*Assuming the UK population calendar and cohort-specific incidences for an individual born between 1950 and 1959. Mortality is not accounted for absolute risk esti-
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control for population stratification because genetic background
is shared within families (16, 17).
For both RAD51C and RAD51D pathogenic variants, the TOC
incidence markedly increases and peaks around ages 58–
60 years compared with the country- and cohort-specific popu-
lation incidences. Even though this is the largest study to date,
the age-specific results were based on relatively small numbers
in each age group. If this pattern is replicated by other studies, it
may have implications on the timing of risk-reducing
interventions.
We used variant frequencies estimated from the United
Kingdom (RAD51C: 0.00022; RAD51D: 0.00026). These are similar
to other frequency estimates. Following the same pathogenic
variant selection criteria, the variant frequencies were esti-
mated to be 0.00055 for RAD51C and 0.0003 for RAD51D using
European non-Finnish noncancer gnomAD data and 0.0007 for
RAD51C and 0.0004 for RAD51D from Song et al. (18). Therefore,
our results are unlikely to have been influenced by incorrect
assumptions for the population variant frequencies.
To maximize the number of families used in the analyses,
for studies with data available for all families used in the muta-
tion screening process, we used both families in which patho-
genic variants were detected and families without pathogenic
variants, under the assumption that the mutation screening
sensitivity is 100%. Our analyses, which assumed reduced mu-
tation screening sensitivity, suggest that if this is substantially
lower (approximately 60%), the estimated risks may have been
somewhat underestimated. The results were very similar to the
main results for the most plausible values of 80–90%.
Women diagnosed with cancer were censored at the age of
risk-reducing surgery if the surgery occurred at least 1 year prior
to cancer diagnosis. We repeated the analysis assuming women
were censored at the age of risk-reducing surgery plus 1 year for
both affected and unaffected. The results were almost identical
to the main analysis (Supplementary Table 12, available online)
suggesting that this assumption is unlikely to have led to bias
in the results because of unequal counting of person-time.
The most parsimonious models incorporated a residual
polygenic component, which also modifies the TOC and BC risk
for pathogenic variant carriers. This indicates that other unob-
served genetic or environmental risk factors shared in families
may modify cancer risks for pathogenic variant carriers, consis-
tent with results on other susceptibility genes [eg, BRCA1,
BRCA2, PALB2 and CHEK2 (10, 11, 19–23)]. These may include the
combined effects of common genetic variants (polygenic risk
score) identified through genome-wide association studies,
which have been shown to modify TOC and BC risks for patho-
genic variant carriers in other genes (24, 25). The results pre-
sented here imply that cancer family history should be
considered when counseling carriers with RAD51C or RAD51D
pathogenic variants because it can lead to large differences in
the cumulative TOC and BC and thus influence clinical manage-
ment. For example, the cumulative risk of TOC to age 80 years
could be as high as 20–23% for a woman with a RAD51C or
RAD51D pathogenic variant if her mother developed TOC at age
55 years (Figure 2; Supplementary Tables 10 and 11, available
online). Similarly, a woman with a RAD51C or RAD51D patho-
genic variant and a first-degree relative diagnosed with BC at a
young age would be classified as high risk (30%) of developing
BC on the basis of the current National Institute for Health and
Care Excellence guidelines in the United Kingdom (26).
The current study has several limitations. Although this is
the largest study of its kind to date, we were not able to assess
variations in risks by variant type or location. Similarly, the
number of TOC and BC cases in some age groups remains small,
and age-specific relative risk estimates are associated with large
standard errors (Table 2). Previous studies have suggested that
pathogenic variants in RAD51C or RAD51D may be more strongly
associated with specific BC subtypes, in particular estrogen re-
ceptor–negative or triple-negative BC (5, 6). No cancer subtype
analyses were performed for either BC or TOC. To estimate
subtype-specific associations in this study design requires tu-
mor pathology data being available on all family members diag-
nosed with BC or TOC, but these were not available.
Nevertheless, our BC risk estimates will still be of clinical
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relevance as current screening or other interventions do not
distinguish between the risks for different BC subtypes. The
analysis was restricted to studies from Europe and North
America. Further studies are needed when applying our find-
ings to other populations.
It has been recently suggested that risk-reducing salpingo-
oophorectomy may be offered to women with more than 4–5%
lifetime risk of TOC (27, 28). The current cumulative risk esti-
mates and associated confidence intervals place both RAD51C
and RAD51D pathogenic variant carriers in the category of
women for whom risk-reducing salpingo-oophorectomy could
be recommended for prevention. However, unlike BRCA1 patho-
genic variants, this may be warranted only for women older
than 50 years, which allows for women of childbearing age to
complete their families. Although the average risk estimates of
BC for RAD51C/RAD51D pathogenic variant carriers would place
these women in the moderate risk category, in combination
with family history of BC, the cumulative risks could be as high
as 46% (Figure 2), which would place them in the high-risk cate-
gory based on the National Institute for Health and Care
Excellence guidelines (26).
In summary, we refined and provided age-specific TOC risk
estimates for women with RAD51C and RAD51D pathogenic var-
iants. We also confirmed that both RAD51C and RAD51D patho-
genic variants confer a moderate risk of BC. Our results suggest
that the RAD51C and RAD51D genes should be included in gene
panel testing for TOC and BC to guide cancer surveillance and
prevention. Incorporation of RAD51C and RAD51D into risk pre-
diction models should be considered to facilitate stratified TOC
and BC risk management.
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Lindblom, and Emma Tham; Umeå University Hospital: Beatrice
Melin; and Uppsala University Hospital: Ylva Paulsson-
Karlsson. The Australian Ovarian Cancer Study Group was sup-
ported by the U.S. Army Medical Research and Materiel
Command under DAMD17-01-1-0729, The Cancer Council
Victoria, Queensland Cancer Fund, The Cancer Council New













edish School of Social Science, U
niversity of H
elsinki user on 09 February 2021
Council Tasmania and The Cancer Foundation of Western
Australia (Multi-State Applications 191, 211 and 182) and the
National Health and Medical Research Council of Australia
(NHMRC; ID199600; ID400413 and ID400281). The AOCS grate-
fully acknowledges additional support from Ovarian Cancer
Australia and the Peter MacCallum Foundation. The AOCS also
acknowledges the cooperation of the participating institutions
in Australia and acknowledges the contribution of the study
nurses, research assistants and all clinical and scientific collab-
orators to the study. The complete AOCS Study Group can be
found at www.aocstudy.org. We would like to thank all of the
women who participated in these research programs.
References
1. Meindl A, Hellebrand H, Wiek C, et al. Germline mutations in breast and ovar-
ian cancer pedigrees establish RAD51C as a human cancer susceptibility
gene. Nat Genet. 2010;42(5):410–414.
2. Loveday C, Turnbull C, Ramsay E, et al. Germline mutations in RAD51D con-
fer susceptibility to ovarian cancer. Nat Genet. 2011;43(9):879–882.
10.1038/ng.893
3. Loveday C, Turnbull C, Ruark E, et al. Germline RAD51C mutations confer
susceptibility to ovarian cancer. Nat Genet. 2012;44(5):475–476; author reply
476. 10.1038/ng.2224 22538716
4. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer
susceptibility genes among a large triple-negative breast cancer cohort unse-
lected for family history of breast cancer. J Clin Oncol. 2015;33(4):304–311.
5. Li N, McInerny S, Zethoven M, et al. Combined tumor sequencing and case/
control analyses of RAD51C in breast cancer. J Natl Cancer Inst. 2019;111(12):
1332–1338.
6. Shimelis H, LaDuca H, Hu C, et al. Triple-negative breast cancer risk genes
identified by multigene hereditary cancer panel testing. J Natl Cancer Inst.
2018;110(8):855–862.
7. Antoniou AC, Pharoah PDP, McMullan G, et al. A comprehensive model for fa-
milial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer.
2002;86(1):76–83.
8. Antoniou AC, Easton DF. Polygenic inheritance of breast cancer: implications
for design of association studies. Genet Epidemiol. 2003;25(3):190–202.
9. Lange K, Weeks D, Boehnke M, MacCluer JW, MacCluer JW. Programs for pedi-
gree analysis: MENDEL, FISHER, and dGENE. Genet Epidemiol. 1988;5(6):
471–472.
10. Antoniou AC, Casadei S, Heikkinen T, et al. Breast-cancer risk in families
with mutations in PALB2. N Engl J Med. 2014;371(6):497–506.
11. Yang X, Leslie G, Doroszuk A, et al. Cancer risks associated with germline
PALB2 pathogenic variants: an international study of 524 families. J Clin
Oncol. 2019;38(7):674–685.
12. Antoniou AC, Pharoah PD, McMullan G, Day NE, Ponder BA, Easton D.
Evidence for further breast cancer susceptibility genes in addition to BRCA1
and BRCA2 in a population-based study. Genet Epidemiol. 2001;21(1):1–18.
13. Cannings C, Thompson EA. Ascertainment in the sequential sampling of
pedigrees. Clin Genet. 2008;12(4):208–212.
14. Ewens WJ, Shute NC. A resolution of the ascertainment sampling problem. I.
Theory. Theor Popul Biol. 1986;30(3):388–412.
15. Shute NC, Ewens WJ. A resolution of the ascertainment sampling problem.
III. Pedigrees. Am J Hum Genet. 1988;43(4):387–395.
16. Thomas DC, Witte JS. Point: population stratification: a problem for case-
control studies of candidate-gene associations? Cancer Epidemiol Biomarkers
Prev. 2002;11(6):505–512.
17. Witte JS, Gauderman WJ, Thomas DC. Asymptotic bias and efficiency in case-
control studies of candidate genes and gene-environment interactions: basic
family designs. Am J Epidemiol. 1999;149(8):693–705.
18. Song H, Dicks E, Ramus SJ, et al. Contribution of germline mutations in the
RAD51B, RAD51C, and RAD51D genes to ovarian cancer in the population. J
Clin Oncol. 2015;33(26):2901–2907.
19. Antoniou AC, Cunningham AP, Peto J, et al. The BOADICEA model of genetic
susceptibility to breast and ovarian cancers: updates and extensions. Br J
Cancer. 2008;98(8):1457–1466.
20. Begg CB. On the use of familial aggregation in population-based case pro-
bands for calculating penetrance. J Natl Cancer Inst. 2002;94(16):1221–1226.
21. Begg CB, Haile RW, Borg A, et al. Variation of breast cancer risk among
BRCA1/2 carriers. JAMA. 2008;299(2):194–201.
22. Johnson N, Fletcher O, Naceur-Lombardelli C, dos Santos Silva I, Ashworth A,
Peto J. Interaction between CHEK2*1100delC and other low-penetrance
breast-cancer susceptibility genes: a familial study. Lancet. 2005;366(9496):
1554–1557.
23. Levy-Lahad E, Lahad A, Eisenberg S, et al. A single nucleotide polymorphism
in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc
Natl Acad Sci USA. 2001;98(6):3232–3236.
24. Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and
contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA.
2017;317(23):2402–2416.
25. Muranen TA, Greco D, Blomqvist C, et al. Genetic modifiers of
CHEK2*1100delC-associated breast cancer risk. Genet Med. 2017;19(5):
599–603.
26. National Institute for Health and Care Excellence (2013). Familial breast cancer:
classification, care and managing breast cancer and related risks in people with a family
history of breast cancer (Clinical Guideline 164). Updated November 2019. https://
www.nice.org.uk/guidance/cg164/. Accessed March 18, 2020.
27. Manchanda R, Legood R, Antoniou AC, Gordeev VS, Menon U. Specifying the
ovarian cancer risk threshold of ‘premenopausal risk-reducing salpingo-oo-
phorectomy’ for ovarian cancer prevention: a cost-effectiveness analysis. J
Med Genet. 2016;53(9):591–599.
28. Manchanda R, Legood R, Pearce L, Menon U. Defining the risk threshold for
risk reducing salpingo-oophorectomy for ovarian cancer prevention in low













edish School of Social Science, U
niversity of H
elsinki user on 09 February 2021
